UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 9, 2015

 

 

Portola Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-35935		20-0216859
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

270 E. Grand Avenue South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 246-7300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 9, 2015 Nicholas Galakatos, a member of the Board of Directors of Portola Pharmaceuticals, Inc. (the “Company”), informed the Company that he does not intend to stand for reelection at the Company’s 2015 annual meeting of stockholders. He advised the Board that his decision was not related to any disagreement with the Company’s operations, policies, or practices. Dr. Galakatos will continue to serve as director and member of the Audit and Compensation Committees until the Company’s 2015 Annual Meeting of Stockholders.

Dr. Galakatos joined the Board in 2003, and the Company thanks Dr. Galakatos for over eleven years of service in successfully guiding the Company through multiple important phases in its history.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				Portola Pharmaceuticals, Inc.
Dated: April 14, 2015
				By:		/s/ Mardi C. Dier
						Mardi C. Dier
						Executive Vice President and Chief Financial Officer